Illumina (NASDAQ:ILMN) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday, February 3rd.
A number of other analysts have also commented on ILMN. Piper Jaffray Companies reiterated an “overweight” rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a research note on Monday, October 9th. Canaccord Genuity reiterated a “buy” rating and issued a $230.00 price target (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Deutsche Bank upgraded shares of Illumina from a “hold” rating to a “buy” rating and reduced their price target for the stock from $195.00 to $160.00 in a research note on Monday, October 23rd. Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. Finally, Robert W. Baird upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $184.00 to $228.00 in a research note on Wednesday, October 25th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $241.39.
Shares of Illumina (NASDAQ ILMN) opened at $220.44 on Friday. The firm has a market cap of $32,180.00, a PE ratio of 44.42, a price-to-earnings-growth ratio of 2.92 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.55 and a current ratio of 3.99. Illumina has a 12 month low of $158.02 and a 12 month high of $248.97.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. Illumina’s revenue was up 25.7% compared to the same quarter last year. During the same period last year, the business earned $0.85 EPS. equities research analysts predict that Illumina will post 4.59 earnings per share for the current year.
In other news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.55, for a total value of $283,187.50. Following the transaction, the director now owns 9,088 shares of the company’s stock, valued at $2,058,886.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $211.35, for a total transaction of $4,227,000.00. Following the completion of the transaction, the director now directly owns 531,717 shares in the company, valued at approximately $112,378,387.95. The disclosure for this sale can be found here. Insiders have sold 114,440 shares of company stock worth $25,318,904 in the last ninety days. Insiders own 0.89% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Intellectus Partners LLC increased its position in Illumina by 6.6% in the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after purchasing an additional 664 shares during the last quarter. Axiom International Investors LLC DE increased its position in Illumina by 60.9% in the third quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock worth $37,142,000 after purchasing an additional 70,572 shares during the last quarter. Virtu Financial LLC bought a new stake in Illumina in the third quarter worth $577,000. Creative Planning increased its position in Illumina by 9.8% in the fourth quarter. Creative Planning now owns 12,384 shares of the life sciences company’s stock worth $2,706,000 after purchasing an additional 1,107 shares during the last quarter. Finally, Gateway Investment Advisers LLC increased its position in Illumina by 3.5% in the fourth quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock worth $20,912,000 after purchasing an additional 3,202 shares during the last quarter. Institutional investors own 92.04% of the company’s stock.
WARNING: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/14/illumina-ilmn-downgraded-by-bidaskclub.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.